Commemorating 25 years of fighting pancreatic cancer
Learn More

Hirshberg Foundation for Pancreatic Cancer Research

Dedicated to advancing pancreatic cancer research and providing support to patients and their families.

Donate
  • ABOUT THE FOUNDATION
    • Agi’s Story
    • About Us →
      • Mission
      • Directors/Trustees
      • Scientific Advisory Board
      • How Our Journey Began
    • COVID-19 Resources
    • News →
      • Latest News
      • Research News
      • Foundation News
      • UCLA Activity Summary Reports
      • Newsletters
      • Press Room
    • Contact
  • PANCREATIC CANCER
    • About the Pancreas →
      • The Pancreas
      • Cancer Cells
      • Risk Factors
      • Symptoms
      • Diagnosis
      • Prognosis
      • Staging
      • Second Opinion
    • Treatment Options →
      • Surgery
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Alternative Treatment Options
      • Clinical Trials
    • Supportive Care →
      • Obstructions
      • Pain Control
      • Nutrition
      • Cannabis
      • Palliative Care
    • Pancreatic Cancer Facts
    • Glossary of Terms
    • Frequently Asked Questions
  • RESEARCH
    • Seed Grant Program →
      • Seed Grant Recipients
      • Frequently Asked Questions
    • UCLA Program →
      • UCLA Center for Pancreatic Diseases
      • Basic Research
      • Translational Research
      • Sahin-Toth Laboratory
      • UCLA Pancreas Tissue Bank
      • UC Pancreatic Cancer Consortium
      • Simms/Mann Psychosocial →
        • Insights into Cancer
    • American Pancreatic Association
    • NIH Funded Projects
  • PATIENTS & CAREGIVERS
    • Patient Support
    • Caregivers
    • Symposium →
      • Symposium Presentations
    • Patient & Family Webinars
    • Genetic Counseling
    • Financial Aid
    • Resources →
      • Symptom Management Workbook
      • Guidelines for Patients: Pancreatic Cancer
      • Creating Your Health Care Team
      • A Virtual Advocate
      • Patient Tools
  • HOW YOU CAN HELP
    • You Can Help Funds
    • Host Your Own Event
    • Event Calendar
    • Get Inspired
    • November Awareness Month →
      • World Pancreatic Cancer Day
    • Other Ways to Give →
      • Shop Online Store
      • Wedding Program
      • Volunteer
      • Planned Giving
      • Car Program
  • SEARCH
Home / News / Research Into The Pancreatic Cancer Microenvironment May Provide Novel Treatment Avenues

Research Into The Pancreatic Cancer Microenvironment May Provide Novel Treatment Avenues

Newly published research investigates the role of stellate cells in the tumor microenvironment and how they may be used to inhibit tumor growth

July 16, 2019

Pancreatic cancer is one of the most difficult cancers to treat in part because of the poorly understood and complex mechanisms of disease progression. Pancreatic cancer is characterized by the infiltration of multiple inflammatory cell types that surround the tumor, known as the tumor microenvironment. This microenvironment is harsh and nutrient-poor yet cancer cells continue to adapt and grow. Research by 2017 Seed Grant Awardee Mara Sherman, PhD seeks to better understand how the interaction of the tumor microenvironment and cancer cells fuels tumor growth in order to find better treatment options.

New research published in Cancer Discovery by Dr. Sherman, of Oregon Health & Science University, found that a specific cell type within the pancreatic tumor microenvironment known as stellate cells have evolved mechanisms to “feed” energy to cancer cells. These stellate cells simultaneously regulate the expression of cancer-supportive genes by tumor cells and secrete factors that promote the survival and growth of cancer cells.

Dr. Sherman’s research demonstrated that inhibition of this energy-providing mechanism drastically suppressed pancreatic tumor growth. This suggests that there are potential avenues for treatment through targeting the metabolic pathways of the stellate cells.

While further investigation is needed, this study is an important stepping stone in understanding the pancreatic cancer microenvironment. Dr. Sherman’s research suggests that despite the statistics, pancreatic cancer may have a novel metabolic vulnerability, which may be targetable for therapeutic benefit.

Read Dr. Sherman’s full paper at Cancer Discovery.


Dr. Sherman and Jurre Kamphorst, PhD, a co-author on this study, were interviewed as part of the National Cancer Institute’s RAS Initiative. From their website:

More than 30 percent of all human cancers – including 95 percent of pancreatic cancers and 45 percent of colorectal cancers — are driven by mutations of the RAS family of genes. NCI established the RAS initiative in 2013 to explore innovative approaches for attacking the proteins encoded by mutant forms of RAS genes and to ultimately create effective, new therapies for RAS-related cancers.

You can read the interview with Drs. Sherman & Kamphorst on the NCI’s website.

Filed Under: News, Research

New research illuminates complex architecture of pancreatic cancer tumors
22nd LA Cancer Challenge Honorary Medical Chair to be Dr. Timothy Donahue of UCLA

Patient Support Resources

from the comfort of your home


Our Webinar Library »

Never Give Up.
The journey continues with an end in sight.
Our Stories »
SUBSCRIBE
Our Free E-Newsletter
Sign up to receive information on breaking news, patient programs and upcoming events.
You can custom tailor your subscriptions and unsubscribe at any time.
  • How You Can Help
  • Make A Donation
  • Host an Event
  • Shop Online Store
  • Signature Events
  • L.A. Cancer Challenge
  • Tour De Pier
  • Hirshberg Training Team
  • More
  • News
  • Press
  • Contact

Stay Connected

Join Our E-newsletter

  • Legal and Privacy
  • Contact Us